目的观察急支汤治疗社区获得性肺炎(痰热壅肺证)的临床疗效。方法将60例社区获得性肺炎患者按随机数字表法随机分为治疗组和对照组各30例。对照组给予静脉滴注头孢哌酮钠舒巴坦钠。治疗组此基础加用急支汤治疗。两组疗程均为7~14 d。结果治疗组治疗后在咳嗽、发热、肺部音症状体征评分显著优于对照组(P〈0.05或P〈0.01)。治疗组在咳嗽、咯痰消失时间、退热时间和肺部音消失时间显著低于对照组(P〈0.05或P〈0.01)。治疗组总有效率90.00%,明显高于对照组的66.67%(P〈0.05)。两组治疗后血清白细胞介素-1β(IL-1β)、肿瘤坏死因子-α(TNF-α)均较治疗前均明显降低(P〈0.01);两组比较,治疗组血清IL-1β、TNF-α下降更显著(P〈0.01)。结论在抗生素为基础治疗的同时加用急支汤治疗治疗社区获得性肺炎(痰热壅肺证)疗效肯定,能够明显改善发热、咳嗽、咯痰等临床症状、体征,并能降低血清中IL-1β和TNF-α炎症因子水平。
Objective: To investigate the clinical effects of acute bronchitis soup on community-acquired pneu- monia. Methods: 60 cases of patients with community-acquired pneumonia were randomly divided into the treat- ment group and the control group,30 cases in each group. The control group received cefoperazone sulbactam sodium for injection 2.0 g,and added 100ml or 250 mL saline,intravenous infusion,2 times/d. The treatment group with acute bronchitis were treated with antibiotic-based therapy simultaneously. The treatment lasted for 7 d to 14 d. Results: For the treatment group after treatment ,cough ,fever,pulmonary tales signs and symptoms score were significantly better than those of the control group;the difference was significant (P〈 0.05 or P〈 0.01 ). As for the treatment group,cough,sputum disappearing time,cooling time and pulmonary rales disappearing time were significantly lower than those of the control group ;the difference was significant (P 〈 0.05 or P 〈 0.01 ). The total effective rate was 90.0% in the treatment group ,the control group 66.7% ;the difference was statistically signifi- cant(P〈 0.05). Serum IL-I[3 and TNF-a after treatment were significantly lower than those before treatment (P〈 0.01 ) and these data of the treatment group were better than those of the control group (P〈 0.01). Conclusions: Based on antibiotic therapy ,with the addition of acute bronchitis soup ,the treatment on community-acquired pneumonia (phlegm-heat obstructing lungs) is effective and can significantly improve fever,cough,sputum and other clinical symptoms and signs, and reduce inflammatory factor levels of serum IL -1β and TNF-α.